LAVA Therapeutics NV - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of this page for potential risks for LAVA Therapeutics NV based on sector, geography and marketcap. The webpage includes a Q&A section about LAVA Therapeutics NV. The analysis of LAVA Therapeutics NV employs data points from across the internet as well as from available disclosures by LAVA Therapeutics NV.
LAVA Therapeutics NV in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 0.0, social score of 1.6 and governance score of 2.0.
1.2
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Analytik Jena AG | 8.0 | High |
1 | Amniotics AB (publ) | 8.0 | High |
... | ... | ... | |
153 | Spark Therapeutics Inc | 1.3 | Low |
153 | Takung Art Co Ltd | 1.3 | Low |
158 | LAVA Therapeutics NV | 1.2 | Low |
158 | Affymetrix Inc | 1.2 | Low |
158 | Aralez Pharmaceuticals Canada Inc | 1.2 | Low |
182 | Wesana Health Holdings Inc | 0.0 | Low |
182 | rEVO Biologics Inc | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does LAVA Therapeutics NV have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose current and historical energy intensity?
Sign up for free to unlockDoes LAVA Therapeutics NV report the average age of the workforce?
Sign up for free to unlockDoes LAVA Therapeutics NV reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose its ethnicity pay gap?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose cybersecurity risks?
Sign up for free to unlockDoes LAVA Therapeutics NV offer flexible work?
Sign up for free to unlockDoes LAVA Therapeutics NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose the number of employees in R&D functions?
Sign up for free to unlockDoes LAVA Therapeutics NV conduct supply chain audits?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes LAVA Therapeutics NV conduct 360 degree staff reviews?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose the individual responsible for D&I?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose water use targets?
Sign up for free to unlockDoes LAVA Therapeutics NV have careers partnerships with academic institutions?
Sign up for free to unlockDid LAVA Therapeutics NV have a product recall in the last two years?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose incidents of discrimination?
Sign up for free to unlockDoes LAVA Therapeutics NV allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas LAVA Therapeutics NV issued a profit warning in the past 24 months?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose parental leave metrics?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose the pay ratio of women to men?
Sign up for free to unlockDoes LAVA Therapeutics NV support suppliers with sustainability related research and development?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes LAVA Therapeutics NV reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs LAVA Therapeutics NV involved in embryonic stem cell research?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose its waste policy?
Sign up for free to unlockDoes LAVA Therapeutics NV report according to TCFD requirements?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose energy use targets?
Sign up for free to unlockDoes LAVA Therapeutics NV disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes LAVA Therapeutics NV have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for LAVA Therapeutics NV
These potential risks are based on the size, segment and geographies of the company.
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.